7 results about "Regimen" patented technology

A device and methods for performing a closed-chain exercise for the lower extremities of a human subject and, in particular, the legs, using stimulation. The device may include a sled for receiving the subject and for translating to and fro between a first, lower position in which the legs are at least partially bent and a second, higher position in which the legs are less bent than in the first position. A stimulator is provided for facilitating the performance of the closed-chain leg exercise by the subject to move the sled between the first and second positions, either by way of electrical signals provided directly to the applicable muscles or by way of sensory (e.g., visual) stimulation, with or without electro-muscular stimulation. In another aspect, adaptive feed-forward control may also be used to enhance the exercise regimen performed using the device.

Described herein is a gym exercise controller device that configures workout routines. The controller allows the user to create a daily workout regimen and also incorporates a workout skip calculation. The controller tracks the performance of a user on the respective exercises apparatuses and provides the user an option to change his/her workout routine based on a performance parameter of the user as well as a comparison of the user's performance parameter to the performance parameter of a group of users.

The present invention relates to a method for identifying a VISA strain in a sample comprising measuring SAV2095 expression levels, a kit and use of SAV2095 for same. The present invention also relates to a method for facilitating the development of an individualized treatment regimen comprising measuring the expression level of SAV2095. The present invention further relates to a method for monitoring the progression of a vancomycin treatment of an infection comprising measuring the expression level of SAV2095. The present invention also relates to the detection of Staphylococcus aureus in a sample.

The invention relates to a Chinese medicinal preparation for treating spermophlebectasia, wherein the reactive constituents are prepared from the following raw materials (by weight portion): ledebouriella root 6-12, dahurian angelica root 6-9, dried orange peel 8-10, red peony root 6-9, Chinese angelica root 9-12, pangolin scales 9-12, Chinese honey locust 9-12, myrrh 3-5, licorice root 4-6, honeysuckle flower 10-15, root of Chinese trichosannthes 10-15, bupleurum root 4-6, Sichuan fritillary bulb 9-12, frank incense 3-6, phellodendron bark 8-10, plantain seeds 8-10. The medicament can be prepared into dose forms of oral liquids, capsules, tablets, pills or powders.

The invention discloses an enema preparation for treating diabetic nephropathy, prepared from the following medicinal raw materials in parts by weight: 20-40 parts of round cardamom, 20-40 parts of juniper, 20-40 parts of salvia miltiorrhiza, 20-40 parts of bezoar, 5-15 parts of bear gall, 10-15 parts of Chinese violet and 2-5 parts of senna leaf. The preparation method comprises the following steps of: taking the medicinal raw materials, mixing, immersing in water, decocting for 60-90 minutes, and filtering to obtain the decoction, namely the enema preparation for treating diabetic nephropathy. The enema preparation is applied as follows: about 150g of decoction is used for enema once before sleep at night, one course of treatment lasts for 20 days, and enema is performed twice per day for patients with serious symptoms. The enema preparation disclosed by the invention has the efficacies on expelling toxin, promoting urination and promoting the subsidence of swelling, has the advantages of definite curative effect, low price, easiness of preparation, acceptability of patients and the like, can delay the development of diabetic nephropathy, can become an important measure for conservative treatment in the azotemia stage of diabetic nephropathy, and has very high clinical use value.

A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In certain embodiments, the dose of tramadol is from about 45 mg to about 80 mg and the second (and optionally) third doses are intravenously administered at intervals of from about 2 to about 3 hours, and thereafter the tramadol is intravenously administered at a dosing interval of about 4 to about 6 hours, until the patient no longer requires treatment with tramadol. In preferred embodiments, the intravenous dosing regimen provides a Cmax and AUC of tramadol is similar to the Cmax and AUC of an oral dose of 100 mg tramadol HCl given every 6 hours. In certain preferred embodiments, the dosing regimen comprises 50 mg IV tramadol at Hour 0, followed by 50 mg at Hour 2, 50 mg at hour 4, and 50 mg every 4 hours thereafter (e.g., until the patient no longer requires treatment with tramadol).

The invention discloses a child pollen anti-allergic drug raw material formula, which comprises a raw material medicine composition comprising the following weight ratios: 7-12 part of ginseng, 9-18 parts of schizonepeta, 12-15 part of honeysuckle, 6-12 parts of dried orange peel, 13-24 parts of coix see, 12-23 parts of rhizoma bletilla, 14-22 parts of astragalus root, 3-7 parts of evodia rutaecarpa, 7-12 parts of rhizoma pinelliae Preparata, 6-13 parts of rhodiola root, 7-16 parts of placenta and 3-7 parts of perilla fructus. The Chinese-medicinal materials have good effect on preventing andtreating allergic diseases, short course of treatment, quick effect, little side effect, little harm to children, and good taste.